In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transgene SA

Division of Institut Merieux
www.transgene.fr

Latest From Transgene SA

Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.

Financing StartUps and SMEs

Transgene Downplays Impact Of Pexa-Vec Phase III Cancer Trial Failure

A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.

Clinical Trials Research & Development

Targovax Pivots Towards Oncolytic Viruses

Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.

 

Cancer ImmunoOncology

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Institut Merieux
  • Senior Management
  • Philippe Archinard, PhD, Chmn. & CEO
    Jean-Philippe Del, VP, Fin.
    Thibaut du Fayet, PhD, VP, Alliance Mngmt., Project Mngmt. & Mktg.
    Maud Brandely, MD, PhD, CMO
  • Contact Info
  • Transgene SA
    Phone: (33) 3 88 27 91 00
    400 Boulevard Gonthier d'Anderach
    Illkirch Graffenstaden, F-67405
    France
UsernamePublicRestriction

Register